
DermNexus 2026 experts explored advances in CSU management and targeted nonsteroidal therapies for psoriasis, atopic dermatitis, and vitiligo.

DermNexus 2026 experts explored advances in CSU management and targeted nonsteroidal therapies for psoriasis, atopic dermatitis, and vitiligo.

DermNexus 2026 experts explored OX40, JAK, TYK2, and BTK pathways, highlighting their roles in personalized inflammatory skin disease treatment.